AL-LAD

Class-level data for serotonergic psychedelics indicate mild, transient cardiovascular stimulation. Individuals with pre-existing cardiovascular conditions (hypertension, arrhythmias, structural heart disease) may face elevated risk. No AL-LAD-specific cardiovascular data published.

schizophrenia, schizoaffective disorder, schizotypal personality disorder

Serotonergic psychedelics can trigger acute psychotic episodes or worsen existing psychotic illness. This is a class-level absolute contraindication documented across LSD and psilocybin literature (Goldberg et al. 2020). No AL-LAD-specific data, but mechanism is shared.

generalized anxiety disorder, panic disorder, major depressive disorder, bipolar disorder

Individuals with anxiety or mood disorders face increased risk of acute distress, panic, and challenging psychological experiences. Pre-existing anxiety disorders are also identified as a risk factor for HPPD (Halpern et al. 2018). This is a relative rather than absolute contraindication — therapeutic psychedelic use in mood disorders is an active research area for other serotonergic psychedelics.

No reproductive or developmental toxicity data have been published for AL-LAD. In the absence of safety data, psychoactive substance use during pregnancy is contraindicated as a precautionary measure.

Concurrent lithium use with serotonergic psychedelics is associated with increased seizure risk at the class level. No AL-LAD-specific case data exist, but this interaction is consistently reported for LSD. The combination is classified as an absolute contraindication due to seizure severity.

Tramadol inhibits serotonin reuptake and lowers seizure threshold. Combined with AL-LAD's serotonergic agonism, this creates risk of serotonin syndrome and seizures. Park et al. (2014) documented serotonin syndrome risk when tramadol is combined with serotonergic agents. No AL-LAD+tramadol case reports exist.

MAOIs block serotonin metabolism, potentially causing dangerous serotonin accumulation when combined with AL-LAD's direct serotonergic agonism. This is a well-established class-level interaction for serotonergic drugs. No AL-LAD-specific case data.

SSRIs and SNRIs can both reduce AL-LAD's psychedelic effects and increase serotonin syndrome risk. The net effect is unpredictable without controlled study. Users on chronic SSRI/SNRI therapy should be aware of both diminished efficacy and increased safety risk.